Management Shake-Ups Consistent in RNAi, microRNA Markets Over Two Years

Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.